RE:RE:RE:On Breakthrough designation, ImmunityBio went for 1.4$ to 7$By doing a jv, TLT would get an upfront payment (1-2-3B$+) and royalties (10%+), in exchange of the rights sold to the big pharma (as TLT cannot distribute it alone).
Usually, and we've seen this with many oncology drugs, market valuation becomes serious 800M$US for those that might sound serious prospect but that are not yet there (still too early in the clinical process, etc ...). Then, the next levels vary between 2.5B$ to 6B$. That's before a drug enters a bidding war. Immunotherapy frenzy back 3-4 years ago (seen as THE holy grail) have seen price tags for takeover in the 8-10B$ range.
What's unique with TLT, assuming 70%+ %CR, is that we are not an adjuvant and we destroy instantly. And we don't need to tema up with other drugs (combos). And such a high %CR would wipe out any future R&D in the future. So that would mean total domination of a market for decades, with no other PDCs in sight either from competition. Then add the frenze of Rutherrin once the market discover us and its possible that we mimic a quick valuation like IBRX experienced. And because we now have a anti-virus platform that targets similar viruses as BioNTech, then we can become a darling of the market (discovery of PDT/PDC, technology that destroys instantly, with no side effect, etc ...).
But lets first wait the next round of data , just to confirm where we stand for real. Just to do things in the proper order.